Lipistad

Atorvastatin, the active ingredient in Lipistad, is a HMG‑CoA reductase inhibitor presented as an oral dosage form for oral use. It treats hypercholesterolemia, mixed dyslipidemia and is used in primary and secondary prevention of cardiovascular disease in adult patients. GNH USA supplies Lipistad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Atorvastatin acts on lipid metabolism pathways to lower abnormal cholesterol levels. - Hypercholesterolemia: reduces low‑density lipoprotein (LDL) cholesterol to target goals. - Mixed dyslipidemia: lowers triglycerides and raises high‑density lipoprotein (HDL) cholesterol. - Primary prevention of cardiovascular disease: decreases risk of heart attack and stroke in at‑risk individuals. - Secondary prevention of cardiovascular disease: helps prevent recurrent events in patients with established disease.

Common Side Effects: - Muscle pain or weakness: mild myalgia reported by some patients. - Elevated liver enzymes: transient increases in ALT or AST. - Gastrointestinal upset: nausea, abdominal discomfort or constipation. - Headache: occasional mild to moderate headache. - Dizziness: occasional sensation of light‑headedness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown that can lead to kidney injury. - Acute liver injury: rare cases of hepatitis or hepatic failure. - Severe allergic reactions: including rash, angioedema or anaphylaxis. - Myopathy with marked CK elevation: muscle toxicity requiring discontinuation. - Pancreatitis: very rare inflammatory pancreatic events.

Before initiating therapy, consider the following precautions. - Pregnancy: contraindicated (Category X) due to risk of fetal harm. - Liver disease: avoid or monitor closely in patients with active hepatic impairment. - Renal impairment: dose adjustment may be required in severe renal dysfunction. - Drug interactions: review concomitant medications for potential statin interactions. - Monitoring: regularly assess lipid profile and liver function tests. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Atorvastatin may interact with several medicines; categorize as follows. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): increase statin exposure and risk of myopathy. - Gemfibrozil: markedly raises risk of rhabdomyolysis. - High‑dose niacin: enhances muscle toxicity. Moderate Interactions (Monitor Closely): - Antihypertensives: may potentiate blood pressure‑lowering effects. - Warfarin: can increase INR, requiring closer coagulation monitoring. - Beta‑blockers: observe for additive effects on heart rate and muscle symptoms.